Investor Relations

Latest Financial Results

Q2 2022

Quarter Ended Feb 28, 2022

Latest Annual Filing

For Fiscal Year Ending Aug 31, 2021

mail icon

Sign Up For Email Alerts

Receive updates straight into your inbox

Sign up today

Company Overview

Agentix Corp. is a clinical-stage biotechnology company that is dedicated to the development of therapies for metabolic diseases, including type 2 diabetes (T2D), obesity, non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).

There is a need for more treatments as the manifestations of metabolic disease continue to be prevalent in the USA. According to the CDC, over 30 million Americans have T2D1 and approximately 100 million US adults are obese2. Furthermore, an estimated 64 million US adults have NAFLD3. Of those with obesity, over 9% of cases are considered to be severe while it is predicted that 20% of NAFLD cases will progress to NASH.

1. https://www.cdc.gov/diabetes/data/statistics-report/index.html
2. https://www.cdc.gov/obesity/data/adult.html
3. https://liverfoundation.org/for-patients/about-the-liver/diseases-of-the-liver/nonalcoholic-steatohepatitis-information-center/nash-definition-prevalence/

Investor Contact Information

Company

Agentix Corp.
309 Fifth Avenue
New York, NY 10016

Investor Relations

ir@agentixcorp.com

Transfer Agent

West Coast Stock Transfer, Inc.
721 N. Vulcan Avenue
#205
Encinitas, CA 92024
cs@wcsti.com